CytomX Therapeutics, Inc. (CTMX) Stock Price & Analysis
CytomX Therapeutics, Inc. (CTMX) closed at USD 2.29 on Thursday, October 29, 2026, down 2.97% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 2.36; the Oct 29, 2026 session ranged USD 2.25–2.41 on volume of 4,628,701 shares. Market capitalization is $498.99M, with a 52-week range of USD 2.16–8.21 (NMS). Source: Nexqual, retrieved October 29, 2026 at 22:04 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CTMX.md
Key facts (CTMX)
- Last four reported quarters (through Jun 30, 2026): revenue $18.3M, net income -$79.7M (-435.2% margin), free cash flow -$82.5M (SEC filings).
- Analysts: Buy (mean 1.63 on a 1–5 scale) (8 analysts), mean target USD 12.25 (range 6–16).
- Total return with dividends: 1Y -31.2% vs S&P 500 +14.4%; 5Y -61.4% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.07, revenue estimate $10.4M. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: CTMX paid no cash dividend in the last five years.
- Short interest: 22.28% of float (as of 2026-10-15), 10.4 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CTMX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $37.3M | $53.2M | $101M | $138M | $76.2M | $18.3M |
| Operating income | -$116M | -$101M | -$6.5M | $25.0M | -$22.4M | -$87.2M |
| Net income | -$116M | -$99.3M | -$569K | $31.9M | -$17.4M | -$79.7M |
| Free cash flow | -$121M | -$113M | -$56.9M | -$86.5M | -$75.8M | -$82.5M |
| Operating margin | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% | -476.2% |
| Net margin | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% | -435.2% |
| Revenue growth | -45.5% | +42.5% | +90.4% | +36.4% | -44.8% | — |
| Cash + short-term investments | $266M | $95.6M | $175M | $102M | $137M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CTMX)
P/S 27.3x · P/B 1.6x · FCF yield -16.53% · Earnings yield -15.96%
P/E at fiscal year-ends: Dec 2024 2.7x.
Analysts (CTMX)
Consensus Buy (mean 1.63 on a 1–5 scale), 8 analysts; mean target USD 12.25 (low 6, high 16).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | JP Morgan | Target lowered | Overweight | $12 → $11 |
| 2026-08-10 | Guggenheim | Target lowered | Buy | $15 → $14 |
Total return (dividends reinvested) (CTMX)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -31.2% | -61.4% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | -31.3% | -17.3% |
| Volatility (annualized) | 84.2% | 101.7% |
| Max drawdown | -67.0% (Mar 2026→Oct 2026) | -93.8% (Nov 2021→Mar 2025) |
Dividends (CTMX)
CTMX paid no cash dividend in the last five years.
Short interest (CTMX)
42,790,446 shares sold short, 22.28% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 38,639,220 shares (+10.7%). Days to cover: 10.4 (short shares ÷ average daily volume).
CTMX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 6, 2026 | Quarter ended Jun 30, 2026 | −$0.09 | −$0.10 | Beat +10.0% | +3.3% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.10 | −$0.11 | Beat +9.1% | -3.6% |
| Mar 16, 2026 | Quarter ended Dec 31, 2025 | −$0.22 | −$0.09 | Miss −144.4% | +16.5% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.09 | −$0.04 | Miss −$0.05 | -14.0% |
| Aug 7, 2025 | — | — | — | — | +8.3% |
| May 12, 2025 | — | — | — | — | +169.4% |
| Mar 6, 2025 | — | — | — | — | +8.1% |
| Nov 7, 2024 | — | — | — | — | +9.0% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CTMX company outlook (results filed Aug 6, 2026)
- “EX-99.1 2 ctmx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update Varsetatug masetecan ("Varseta-M") Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026.”
- “Dose escalation of CX-801 in combination with KEYTRUDA® has cleared the third dose level and enrollment into the study continues. • Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027.”
Quoted word-for-word from the SEC 8-K results press release.
CTMX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.07 | $-0.11 | +$0.03 | $10.4M | 7 |
| Next quarter (ends Dec 2026) | $-0.10 | $-0.11 | +$0.01 | $5.3M | 7 |
| Current fiscal year (ends Dec 2026) | $-0.39 | $-0.42 | +$0.03 | $25.0M | 7 |
| Next fiscal year (ends Dec 2027) | $-0.47 | $-0.49 | +$0.02 | $25.3M | 7 |
CTMX options: expected move
Options price a move of about ±29.1% (±$0.69) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±29% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 143.7% | ±29.1% |
| Jan 15, 2027 | 78 | 172.6% | ±57.4% |
| Feb 19, 2027 | 113 | 121.3% | ±46.8% |
| May 21, 2027 | 204 | 119.2% | ±63.8% |
30-day implied volatility 167.9% vs 61% realized over the last 30 trading days. Put/call ratio (volume) 0.11. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 22:04 UTC)
| Price | USD 2.29 |
|---|---|
| Change | ▼ 2.97% (down) |
| Previous Close | USD 2.36 |
| Open | USD 2.38 |
| Day Range | USD 2.25 – 2.41 |
| 52-Week Range | USD 2.16 – 8.21 |
| Volume | 4,628,701 shares |
| Market Cap | $498.99M |
| Exchange | NMS |
Technical Analysis (CTMX)
Nexqual's technical model rates CTMX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 22:04 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.61 (neutral) |
| vs SMA50 | Below (USD 2.85) |
| MACD | -0.14 (negative) |
Analyst Ratings (CTMX)
Wall Street analysts rate CTMX "Buy" based on 8 analysts, with a mean price target of USD 12.25 (range USD 6–16), per Nexqual as of October 29, 2026 at 22:04 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 12.25 |
| High Target | USD 16 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CTMX)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $10.45M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.09 vs est -0.1 ▲ beat |
| 2026-03-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-12-31 | USD -0.22 vs est -0.09 ▼ miss |
| 2025-09-30 | USD -0.09 vs est -0.04 ▼ miss |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
Financials & Fundamentals (CTMX)
| Total Revenue | $18.30M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -92.40% |
| Gross Margin | +100.00% |
| Operating Margin | -1677.08% |
| Profit Margin | +0.00% |
| ROE | -37.75% |
| Debt / Equity | 0.02 |
| Current Ratio | 9.36 |
| Total Cash | $330.28M |
| Total Debt | $5.70M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$82.48M (-450.7% of revenue) |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
Financial Health Score (CTMX)
Nexqual rates CytomX Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 22:04 UTC.
| Growth | Critical — Revenue -45% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $330M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$82M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -26%, ROA -20.9% (last 4 quarters, SEC) |
Ownership (CTMX)
| Insider Ownership | +0.57% |
|---|---|
| Institutional Ownership | +104.77% |
| Shares Outstanding | 217.90M |
| Float | 179.66M |
| Short % of Float | +22.28% |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
Leadership (CTMX)
CytomX Therapeutics, Inc. is led by Sean A. McCarthy DPHIL, Chairman & CEO, per Nexqual as of October 29, 2026 at 22:04 UTC.
| Chairman & CEO | Sean A. McCarthy DPHIL |
|---|---|
| SVP, CFO & Secretary | Christopher W. Ogden |
| Senior VP & Chief Scientific Officer | Marcia P. Belvin |
| Senior Vice President of Intellectual Property | Leslie Robbins |
| Senior Vice President of Quality & Product Manufacturing | Dawn Benson |
Major Backers & Investors (CTMX)
Notable institutional backers of CytomX Therapeutics, Inc. include FMR, LLC, Fidelity, Kynam Capital Management, LP, according to Nexqual as of October 29, 2026 at 22:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 15.01% |
| Fidelity | 11.21% |
| Kynam Capital Management, LP | 9.96% |
| Bank of America Corporation | 6.92% |
| Perceptive Advisors Llc | 4.79% |
| Point72 Asset Management, L.P. | 3.58% |
| Wellington Management | 2.37% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.06% |
| State Street | 5.39% |
| Vanguard Group | 3.91% |
Source: Nexqual, October 29, 2026 at 22:04 UTC.
From CytomX Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that our multi-modality PROBODY therapeutic platform provides the following key advantages: A novel biologic therapeutic class enabled by our proprietary platform.
- We are utilizing our proprietary, versatile, multi-modality PROBODY platform to create a pipeline of conditionally activatable biologic therapeutics to improve the lives of people with cancer and to build a long-term, multi-product, commercial biopharmaceutical company.
- Our proprietary masking technologies allow for unique customization of large drug candidate pools from which high potential clinical candidates are selected.
- In March 2020, we entered into a Collaboration and License Agreement (the "Astellas Agreement") with Astellas, pursuant to which we and Astellas will collaborate on the research, development and commercialization of TCE products ("Products") directed to CD3 and selected tumor antigen targets using our PROBODY® platform and other proprietary technology.
Partnerships
- Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million and estimated research and development service fees, and we were initially entitled to receive contingent payments of up to $25.0 million for additional targets and contingent payments for development, regulatory and sales milestones.
- In the second quarter of 2024, CytomX announced a clinical collaboration with Merck to supply KEYTRUDA for evaluation of its combination with CX-801 in the Phase 1 study.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be unable to obtain or be delayed in obtaining U.S. or foreign regulatory approval and, as a result, be unable or delayed in being able to commercialize our product candidates.
- Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval.
- We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad.
- Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 93.07 | ▲ 1.2% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 317.33 | ▼ 0.45% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.65 | ▲ 0.71% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.45 | ▼ 0.04% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.39 | ▼ 1.14% |
| PRAX | Praxis Precision Medicines, Inc | USD 288.62 | ▲ 1.1% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 22:04 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt